These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 8422599)
1. The impact of health care reform on reimbursement for investigational therapy. Turner S Cancer Invest; 1993; 11(1):68-9. PubMed ID: 8422599 [No Abstract] [Full Text] [Related]
3. Breakout II. Reimbursement concerns. Henney JE; Greene T; Aronson N; Johnson JE; McCabe M; Monaco GP; Poulter CA Cancer; 1990 May; 65(10 Suppl):2409-10. PubMed ID: 2334881 [No Abstract] [Full Text] [Related]
4. Impact of third-party reimbursement on cancer clinical investigation: a consensus statement coordinated by the National Cancer Institute. McCabe M; Friedman MA J Natl Cancer Inst; 1989 Oct; 81(20):1585-6. PubMed ID: 2677395 [No Abstract] [Full Text] [Related]
5. Ethical and financial considerations in third-party support of investigational cancer therapies. Young FE Cancer; 1993 Nov; 72(9 Suppl):2854-8. PubMed ID: 8402519 [TBL] [Abstract][Full Text] [Related]
6. How some patients in new-drug trials can get cut off. Anand G Wall St J (East Ed); 2003 Dec; ():A1, A11. PubMed ID: 14971381 [No Abstract] [Full Text] [Related]
7. Reimbursing new technologies: why are the courts judging experimental medicine? Saver RS Stanford Law Rev; 1992 May; 44(5):1095-131. PubMed ID: 10119850 [No Abstract] [Full Text] [Related]
8. A perspective on investigational drug management. Hill DP; Browning DA Top Hosp Pharm Manage; 1993 Apr; 13(1):29-36. PubMed ID: 10128790 [TBL] [Abstract][Full Text] [Related]
10. Health care reform in oncology. Krakoff IH Cancer Invest; 1994; 12(2):235-6; discussion 236-7. PubMed ID: 8131099 [No Abstract] [Full Text] [Related]
11. Are health insurers denying patients quality care? Antoine F J Natl Cancer Inst; 1989 Dec; 81(23):1766-8. PubMed ID: 2619832 [No Abstract] [Full Text] [Related]
12. Viewpoint: hospitals often play important role as intermediaries of patients in clinical research programs. Hochhauser M Patient Care Manag; 2002 Jun; 17(9):1, 4-6. PubMed ID: 12087591 [No Abstract] [Full Text] [Related]
14. Third party reimbursement for participation in cancer clinical trials: a proposal for legislation. Plaue GM J Contemp Health Law Policy; 2000; 16(2):305-54. PubMed ID: 10921232 [No Abstract] [Full Text] [Related]
15. The crisis in clinical cancer research. Third-party insurance and investigational therapy. Antman K; Schnipper LE; Frei E N Engl J Med; 1988 Jul; 319(1):46-8. PubMed ID: 3288868 [No Abstract] [Full Text] [Related]
16. Market watch: Upcoming market catalysts in Q3 2016. Ranj T Nat Rev Drug Discov; 2016 Jul; 15(7):449. PubMed ID: 27282354 [No Abstract] [Full Text] [Related]
17. The impact of clinical trial protocols on patient care systems. Lawrence W; Antman K; Freeman HP; Huber SL; Kaufman D; Lantos J; Lenhard RE; Levine RJ; McKenna RJ; Young FE Cancer; 1993 Nov; 72(9 Suppl):2839-41. PubMed ID: 8402515 [No Abstract] [Full Text] [Related]
18. Medical necessity: do we need it? Bergthold LA Health Aff (Millwood); 1995; 14(4):180-90. PubMed ID: 8690343 [TBL] [Abstract][Full Text] [Related]
19. Coverage denied. Findlay S US News World Rep; 1991 Dec; 111(24):80-2. PubMed ID: 10115716 [No Abstract] [Full Text] [Related]
20. Expanded clinical trials of treatments for multiple sclerosis: copolymer 1 (COP-1) treatment investigational new drug (IND) program. Stark Y Ann Neurol; 1994 Jul; 36(1):114-5. PubMed ID: 8024251 [No Abstract] [Full Text] [Related] [Next] [New Search]